Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies

George Sakoulas; Paul B Eckburg; Maria Amodio-Groton; Amy Manley; Evan Tzanis; Anita F Das; Robert Noble; Paul C McGovern

doi:10.1093/ofid/ofab136

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies

Open Forum Infect Dis. 2021 Jun 18;8(6):ofab136. doi: 10.1093/ofid/ofab136. eCollection 2021 Jun.

Authors

George Sakoulas¹, Paul B Eckburg², Maria Amodio-Groton², Amy Manley², Evan Tzanis², Anita F Das³, Robert Noble², Paul C McGovern²

Affiliations

¹ University of California, San Diego, California, USA.
² Paratek Pharmaceuticals Inc., King of Prussia, Philadelphia, USA.
³ AD Stats Consulting, Guerneville, California, USA.

Abstract

In this post hoc analysis of the 63 patients with secondary bacteremia enrolled in the 3 omadacycline phase 3 studies of acute bacterial skin/skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), we determined that omadacycline is a viable therapeutic option for appropriate patients with secondary bacteremia.

Keywords: acute bacterial skin and skin structure infections; community-acquired pneumonia; efficacy; omadacycline; secondary bacteremia.